article thumbnail

Degree of Weight Loss Affects Tirzepatide-Linked Cardiometabolic Risk Improvement

Physician's Weekly

“Understanding whether there are specific thresholds of weight reduction associated with minimum or maximum cardiometabolic benefits may assist clinicians in tailoring weight reduction goals to individual patients seeking to reduce their cardiometabolic risk,” the authors write. Bruno Linetzky, M.D.,

article thumbnail

How to Get Ozempic & GLP-1’s Covered by Insurance (or Save Big with Plum Health Direct Primary Care): The Ultimate Guide You Can’t Afford to Miss!

Plum Health

Managing diabetes—especially as you get older—can be challenging physically, emotionally, and financially. If you’re living with Type 2 diabetes, you’ve probably heard of Ozempic, Wegovy (semaglutide), Mounjaro or Zepbound (tirzepatide). With Plum Health, managing your diabetes becomes easier, more affordable, and less stressful.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Maine and Nevada Update Drug Price Transparency Laws

FDA Law

Schlanger — Maine and Nevada previously enacted laws requiring drug manufacturers to report information about the pricing of their products. Both states’ new requirements will become effective in October 2021 and should be considered as manufacturers prepare for state drug price transparency reporting in 2022.

article thumbnail

Hearing Loss in Geriatrics and Palliative Care: A Podcast with Nick Reed and Meg Wallhagen

GeriPal

We talk with Nick and Meg about: Why hearing loss is important not just in geriatrics but also for those caring for seriously ill individuals. Communication techniques we can use when talking to individuals with hearing loss. And he liked some of what I was doing, which was really on diabetes and hearing loss.

IT 102
article thumbnail

American Diabetes Association, June 20-23

Physician's Weekly

The annual meeting of the American Diabetes Association was held this year from June 20 to 23 in Chicago, drawing more than 15,000 participants, including clinicians, academicians, allied health professionals, and others interested in diabetes. ” The study was funded by MannKind, the manufacturer of Afrezza. .

article thumbnail

Urinary Incontinence Revisited: George Kuchel & Alison Huang

GeriPal

Incontinence and avoiding issues can present in an older individual, in some cases, just like they do a younger person. Biological aging or physiological aging varies from individual to individual. How do you think about this from a clinical perspective when you’re seeing individuals in your office? Everybody ages.

IT 120
article thumbnail

Patient Groups Sue HHS, CMS for 2020 Rule Allowing the Use of Copay Accumulator Programs

FDA Law

Recognizing the problems that high prescription drug costs pose to patient access to medications, many drug manufacturers have created copay assistance programs to help patients afford the copays and deductibles for their medications. These prohibitions are often referred to as copay accumulator adjustment programs.